Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis

Jian Shen, Ning Song, Christopher J Williams, Celeste J Brown, Zheng Yan, Chen Xu, Larry J Forney, Jian Shen, Ning Song, Christopher J Williams, Celeste J Brown, Zheng Yan, Chen Xu, Larry J Forney

Abstract

Atrophic vaginitis (AV) is common in postmenopausal women, but its causes are not well understood. The symptoms, which include vaginal itching, burning, dryness, irritation, and dyspareunia, can usually be alleviated by low doses of estrogen given orally or locally. Regrettably, the composition of vaginal bacterial communities in women with AV have not been fully characterized and little is known as to how these communities change over time in response to hormonal therapy. In the present intervention study we determined the response of vaginal bacterial communities in postmenopausal women with AV to low-dose estrogen therapy. The changes in community composition in response to hormonal therapy were rapid and typified by significant increases in the relative abundance of Lactobacillus spp. that were mirrored by a decreased relative abundance of Gardnerella. These changes were paralleled by a significant four-fold increase in serum estradiol levels and decreased vaginal pH, as well as nearly a two-fold increase in the Vaginal Maturation Index (VMI). The results suggest that after menopause a vaginal microbiota dominated by species of Lactobacillus may have a beneficial role in the maintenance of health and these findings that could lead to new strategies to protect postmenopausal women from AV.

Figures

Figure 1. Hierarchical clustering of vaginal microbial…
Figure 1. Hierarchical clustering of vaginal microbial communities in healthy postmenopausal women and a heat map showing the log10-transformed proportions of bacterial genera in each community.
The visit time of each sample is indicated by the color-coded bar immediately below the dendrogram. Analysis of similarities in community composition and structure resulted in three clusters as indicated in the color bar above the heatmap.
Figure 2
Figure 2
Interpolated bar plots of phylotype relative abundances in four selected subjects in the H group over 4 weeks (panels A–D). Color key for each phylotype represented in the interpolated bar plots are on the right side.
Figure 3. Canonical variable analysis of vaginal…
Figure 3. Canonical variable analysis of vaginal bacterial communities in healthy women at 0, 2, and 4 weeks (H-0, H-2, and H-4) compared to each other and the vaginal communities of women with AV at 0, 2, and 4 weeks (AV-0, AV-2, and AV-4).
Asterisks indicate communities that were significantly different (P 

Figure 4. Relationships among vaginal bacterial communities…

Figure 4. Relationships among vaginal bacterial communities visualized by principal component analysis (PCA).

Each point…

Figure 4. Relationships among vaginal bacterial communities visualized by principal component analysis (PCA).
Each point corresponds to a single subject at a single time point and was colored according to group membership and time of sampling. The percentages given in the axis labels wee the proportion of variation explained by that principal component. (A) Comparison of vaginal bacterial communities of healthy post-menopausal women at week 0 (green dots) to those of women with atrophic vaginitis at week 0 (red dots). (B) Comparison of vaginal bacterial communities of women with atrophic vaginitis at week 0 (red dot) to those in the AV group after 4 weeks of estrogen therapy (blue dots).

Figure 5. Interpolated bar plots of phylotype…

Figure 5. Interpolated bar plots of phylotype relative abundance observed in four subjects selected from…

Figure 5. Interpolated bar plots of phylotype relative abundance observed in four subjects selected from the AV group.
Color codes for each phylotype represented in the interpolated bar plots are displayed on the right side of the figure. See Supplementary Fig. S2 interpolated bar plots for all subjects.
Figure 4. Relationships among vaginal bacterial communities…
Figure 4. Relationships among vaginal bacterial communities visualized by principal component analysis (PCA).
Each point corresponds to a single subject at a single time point and was colored according to group membership and time of sampling. The percentages given in the axis labels wee the proportion of variation explained by that principal component. (A) Comparison of vaginal bacterial communities of healthy post-menopausal women at week 0 (green dots) to those of women with atrophic vaginitis at week 0 (red dots). (B) Comparison of vaginal bacterial communities of women with atrophic vaginitis at week 0 (red dot) to those in the AV group after 4 weeks of estrogen therapy (blue dots).
Figure 5. Interpolated bar plots of phylotype…
Figure 5. Interpolated bar plots of phylotype relative abundance observed in four subjects selected from the AV group.
Color codes for each phylotype represented in the interpolated bar plots are displayed on the right side of the figure. See Supplementary Fig. S2 interpolated bar plots for all subjects.

References

    1. Sturdee D. W. & Panay N. International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13, 509–522 (2010).
    1. Castelo-Branco C., Cancelo M. J., Villero J., Nohales F. & Juliá M. D. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52S, S46–S52 (2005).
    1. Skouby S. O. et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 51, 8–14 (2005).
    1. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 20, 888–902 (2013).
    1. Simon J. A., Reape K. Z., Wininger S. & Hait H. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil. Steril. 90, 1132–1138 (2008).
    1. Zhou X. et al. Recent advances in understanding the microbiology of the female reproductive tract and the causes of premature birth. Infect. Dis. Obstet. Gynecol. 2010, 737425 (2010).
    1. Ravel J. et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. 108S1, 4680–4687 (2011).
    1. Raz R. & Stamm W. E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329, 753–756 (1993).
    1. Marx P., Schade G., Wilbourn S., Blank S., Moyer D. L. & Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 47, 47–54 (2004).
    1. Bachmann G., Lobo R. A., Gut R., Nachtigall L. & Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet. Gynecol. 111, 67–76 (2008).
    1. Hummelen R. et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PloS One 6, e26602 (2011).
    1. Sobel J. D. Is there a protective role for vaginal flora? Curr. Infect. Dis. Rep. 1, 379–383 (1999).
    1. Caillouette J. C., Sharp C. F. Jr., Zimmerman G. J. & Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am. J. Obstet. Gynecol. 176, 1270–1277 (1997).
    1. Crandall C. Vaginal estrogen preparations: A review of safety and efficacy for vaginal atrophy. J. Women’s Health 11, 857–877 (2002).
    1. Mirmonsef P. et al. Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. Menopause 22, 702–709 (2015).
    1. Galhardo C. L., Soares J. M., Simoes R. S., Haidar M. A., Rodrigues D. L. G. & Baracat E. C. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin. Exp. Obstet. Gynecol. 33, 85–89 (2006).
    1. Colodner R., Edelstein H., Chazan B. & Raz R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr. Med. Assoc. J. 5, 767–769.(2003).
    1. Mac B. M. B., Rhodes D. J. & Shuster L. T. Vulvovaginal atrophy. Mayo Clin. Proc. 85, 87–94 (2010).
    1. Yoshimura T. & Okamura H. Short term oral estriol treatment restores normal premenopausal vaginal flora to elderly women. Maturitas 39, 253–257 (2001).
    1. Pabich W. L., Fihn S. D., Stamm W. E., Scholes D., Boyko E. J. & Gupta K. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J. Infect. Dis. 188, 1054–1058 (2003).
    1. Cauci S. et al. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J. Clin. Microbiol. 40, 2147–2152.(2002).
    1. Zhang R., Daroczy K., Xiao B., Yu L., Chen R. & Liao Q. Qualitative and semiquantitative analysis of Lactobacillus species in the vaginas of healthy fertile and postmenopausal Chinese women. J. Med. Microbiol. 61, 729–739 (2012).
    1. Petricevic L. et al. Differences in the vaginal lactobacilli of postmenopausal women and influence of rectal lactobacilli. Climacteric 16, 356–361 (2012).
    1. Brotman R. M. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause 21, 450–458 (2014).
    1. Gustafsson R. J. et al. The Lactobacillus flora in vagina and rectum of fertile and postmenopausal healthy Swedish women. BMC Womens Health 11, 17 (2001).
    1. Heinemann C. & Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can. J. Microbiol. 51, 777–781 (2005).
    1. Hillier S. L. & Lau R. J. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clin. Infect. Dis. 25S2, S123–126 (1997).
    1. Hickey R. J. et al. Vaginal microbiota of adolescent girls prior to the onset of menarche resemble those of reproductive-age women. mBio 6(2), e00097–15 (2015).
    1. Linhares I. M., Summers P. R., Larsen B., Giraldo P. C. & Witkin S. S. Contemporary perspectives on vaginal pH and lactobacilli. Am. J. Obstet. Gynecol. 204,120.e1-5 (2011).
    1. Rose W. A. 2nd, McGowin C. L., Spagnuolo R. A., Eaves-Pyles T. D., Popov V. L. & Pyles R. B. Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS One. 7, e32728 (2012).
    1. Bisanz J. E. et al. A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal women. PLoS One. 9, e104511 (2014).
    1. Pybus V. & Onderdonk A. B. Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis. Microbes Infect. 1, 285–92 (1999).
    1. Patterson J. L., Stull-Lane A., Girerd P. H. & Jefferson K. K. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiol. 156, 392–399 (2010).
    1. Gelber S. E., Aguilar J. L., Lewis K. L. & Ratner A. J. Functional and phylogenetic characterization of vaginolysin, the human-specific cytolysin from Gardnerella vaginalis. J. Bacteriol. 190, 3896–3903 (2008).
    1. Libby E. K., Pascal K. E., Mordechai E., Adelson M. E. & Trama J. P. Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis. Microb. Infect. 10, 439–446 (2008).
    1. Hale L. P., Swidsinski A. & Mendling W. Bacteria associated with bacterial vaginosis. N. Engl. J. Med. 354, 202–203 (2006).
    1. Swidsinski A. et al. Adherent biofilms in bacterial vaginosis. Obstet. Gynecol. 106, 1013–1023 (2005).
    1. Mitchell C. M., Fredricks D. N., Winer R. L. & Koutsky L. Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol. 120, 1306–1313 (2012).
    1. Ahmed A. et al. Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars. J. Bacteriol. 194, 3922–3937 (2012).
    1. Willhite L. & O’Connell M. B. Urogenital atrophy: prevention and treatment. Pharmacotherapy 21, 464–480 (2001).

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться